Morteza Yazdani, PhD

Nestlé Health Science, Switzerland

Poster(s):

• (381) Cost-effectiveness of VOWST (fecal microbiota spores, live-brpk; VOS, formerly SER-109) for Prevention of Recurrent Clostridioides difficile Infection in the United States (US)
  Wednesday, October 29, 2025